Astrazeneca (AZN) Projected to Post Earnings on Monday

Astrazeneca (NYSE:AZN) is projected to post its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect Astrazeneca to post earnings of $2.50 per share and revenue of $15.4547 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, July 27, 2026 at 6:45 AM ET.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. On average, analysts expect Astrazeneca to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Astrazeneca Trading Down 0.1%

Shares of AZN stock opened at $168.81 on Monday. Astrazeneca has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock has a market cap of $261.82 billion, a P/E ratio of 25.35, a P/E/G ratio of 1.38 and a beta of 0.24. The business has a fifty day simple moving average of $182.16 and a 200-day simple moving average of $188.44. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AZN. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, Bank of America reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Triumph Capital Management bought a new position in Astrazeneca during the 3rd quarter valued at $25,000. JPL Wealth Management LLC acquired a new stake in shares of Astrazeneca in the 3rd quarter valued at about $35,000. Johnson Financial Group Inc. raised its stake in shares of Astrazeneca by 1,265.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 546 shares of the company’s stock valued at $42,000 after purchasing an additional 506 shares in the last quarter. Acumen Wealth Advisors LLC bought a new position in shares of Astrazeneca during the fourth quarter worth about $47,000. Finally, Binnacle Investments Inc grew its stake in Astrazeneca by 21.8% in the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after purchasing an additional 118 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.